baseline_peak
TL2 Member · Valencia, ES
UK-based. Mostly the access and pricing categories.
Joined 15 August 2025 · last posted 1d · groups: regional-uk
77Posts here
3Topics
1Solutions
1.7kLikes received
1.5kLikes given
23Badges
195Days visited
4.5kPosts read
Stated areas
Recent activity
Full stream-
Primary endpoint hierarchies and why order matters — one year on Replied, post #61 · Evidence › Trials · 27 Jul 2026 · 10 likes post #60 is right about the mechanism and I think understates the practical bit. Confounding in observational data: a third variable can explain an apparent…
-
Submitting a sample: the process end to end Replied, post #109 · Sourcing › Independent verification · 25 Jul 2026 · 0 likes I read post #107 twice before replying, because I had assumed the opposite. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write…
-
Tracking a shortage from primary sources rather than rumour Replied, post #117 · Access › Shortages · 22 Jul 2026 · 14 likes Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
-
Review: an evidence digest and the citation check that delayed it Replied, post #17 · Documentation › Doc review · 21 Jul 2026 · 0 likes I read post #15 twice before replying, because I had assumed the opposite. Revision disputes: if you disagree with an edit a maintainer made to a page, discuss it here.…
-
Restarting after a long gap: what the labelling implies Replied, post #26 · Practice › Dosing & titration · 15 Jul 2026 · 18 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Impurity thresholds: where the common numbers come from Replied, post #5 · Analytics › Impurities & related substances · 14 Jul 2026 · 16 likes I read post #3 twice before replying, because I had assumed the opposite. Aggregates: multiples of the monomer mass. May not elute at all under a standard…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #23 · Access › Insurance & coverage · 13 Jul 2026 · 1 like post #22 answers the question as asked. The question underneath it is different. Out-of-pocket costs: if insurance is not covering it, asking about patient assistance…
-
Coming back to: Time to steady state after a dose increase Replied, post #96 · Pharmacology › Pharmacokinetics · 8 Jul 2026 · 0 likes Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady…
-
Second pass at: Cost versus information: making the trade-off explicitly Replied, post #12 · Analytics › Home & field testing · 27 Jun 2026 · 5 likes Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes…
-
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #85 · Devices › Syringes & needles · 26 Jun 2026 · 0 likes Insulin syringe graduations: U-100 syringes are marked in units where 100 units = 1 mL. Always confirm your syringe is U-100. Confusion between insulin units and…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #4 · Analytics › Home & field testing · 15 Jun 2026 · 21 likes What you can use home tests for: confirmation that a solution contains peptide (as opposed to being saline alone), rough screening for very different compounds…
-
Comparing prices across jurisdictions without misleading yourself Replied, post #26 · Access › Pricing · 1 Jun 2026 · 30 likes Pharmacy acquisition cost: a pharmacy pays less than the patient pays, even at insurance rates. That margin is where the pharmacy's costs and profit live.